DelveInsight’s “Bladder Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Bladder Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Bladder Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Bladder Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Bladder Cancer: An Overview
Bladder cancer (BC) is the most common neoplasm of the urinary system. The wall of the bladder has several layers. Each layer is made up of different kinds of cells and BC begins when healthy cells in the bladder lining—most commonly urothelial cells—change and grow out of control, forming a mass called a tumor. There are multiple known risk factors for BC. Important risk factors include smoking, schistosomiasis infection, and occupational exposure to certain chemicals. Urothelial carcinoma is the most common histologic type of BC. Further, the majority of newly diagnosed bladder cancers (75% to 80%) are classified as non-muscle invasive bladder cancer (NMIBC).
Types of Bladder cancer
There are different types of bladder cancer that begin in the lining of the bladder.
-
Urothelial carcinoma (also called transitional cell carcinoma) is cancer that begins in the urothelial cells, which line the urethra, bladder, ureters, renal pelvis, and some other organs. Almost all bladder cancers are urothelial carcinomas.
-
Squamous cell carcinoma is a cancer that begins in squamous cells (thin, flat cells lining the inside of the bladder). This type of cancer may form after long-term irritation or infection with a tropical parasite called schistosomiasis.
-
Adenocarcinoma is a cancer that begins in glandular cells that are found in the lining of the bladder. Glandular cells in the bladder make mucus and other substances.
-
Small cell carcinoma of the bladder is cancer that begins in neuroendocrine cells (nerve-like cells that release hormones into the blood in response to a signal from the nervous system).
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Bladder Cancer pipeline therapies. It also thoroughly assesses the Bladder Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Bladder Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Bladder Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Bladder Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Bladder Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
Bladder Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Bladder Cancer market or expected to be launched during the study period. The analysis covers the Bladder Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Bladder Cancer drugs based on their sale and market share.
The report also covers the Bladder Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Bladder Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Bladder Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/bladder-cancer-market
Bladder Cancer Therapeutics Analysis
Different types of treatment are available for bladder cancer. The treatment plan is based on the type, stage, and grade of the cancer, and overall health. Some of the treatment involves:
-
Systemic chemotherapy: systemic chemotherapy for bladder cancer is when chemotherapy drugs are injected into a vein. drugs that may be used to treat bladder cancer include carboplatin, cisplatin, doxorubicin, fluorouracil, among others.
-
Intravesical chemotherapy: For bladder cancer, chemotherapy may be intravesical, which means it is put into the bladder through a tube inserted into the urethra. Intravesical treatments flush the bladder with drugs that kill cancer cells that remain after surgery. Mitomycin and gemcitabine are two chemotherapy drugs given as intravesical chemotherapy to treat bladder cancer.
-
Immunotherapy: Systemic immunotherapy drugs used to treat urothelial cancer (a type of bladder cancer) includeavelumab, nivolumab, and pembrolizumab. These drugs work in more than one way to kill cancer cells. Moreover, BCG (bacillus Calmette-Guérin) is an intravesical immunotherapy drug used to treat bladder cancer. BCG is given in a solution that is placed directly into the bladder using a catheter (thin tube).
To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Bladder cancer. Currently, CG Oncology is leading the therapeutics market with its Bladder cancer drug candidates in the most advanced stage of clinical development.
Bladder Cancer Companies Actively Working in the Therapeutics Market Include
Pfizer, Celgene Corporation, Eli Lilly, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, Hoffmann-La Roche, Novartis International, Johnson & Johnson, Merck & Co Inc., Vault Pharma Inc., Vyriad Inc., and many others.
Emerging and Marketed Bladder Cancer Therapies Covered in the Report Include:
-
CG0070: CG Oncology
-
N-803: ImmunityBio
-
UGN-102: UroGen
-
Trilaciclib: G1 Therapeutics
-
APL-1202: Asieris Pharmaceuticals
-
TAR-200: Janssen Research & Development, LLC
-
HX008: Lepu Biopharma
-
Futibatinib: Taiho Oncology, Inc.
-
TLD-1433: Theralase Technologies Inc.
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/bladder-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Bladder Cancer Competitive Intelligence Analysis
4. Bladder Cancer Market Overview at a Glance
5. Bladder Cancer Disease Background and Overview
6. Bladder Cancer Patient Journey
7. Bladder Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Bladder Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Bladder Cancer Unmet Needs
10. Key Endpoints of Bladder Cancer Treatment
11. Bladder Cancer Marketed Therapies
12. Bladder Cancer Emerging Drugs and Latest Therapeutic Advances
13. Bladder Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Bladder Cancer Market Outlook (In US, EU5, and Japan)
16. Bladder Cancer Companies Active in the Market
17. Bladder Cancer Access and Reimbursement Overview
18. KOL Views on the Bladder Cancer Market
19. Bladder Cancer Market Drivers
20. Bladder Cancer Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/bladder-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Asthma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Asthma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Asthma market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/